Strategic Growth AliveDx is expanding its MosaiQ automated high-throughput platform and recently unveiled new multiplex assays, signaling opportunities to upsell advanced diagnostic workflows to large laboratories, hospitals, and blood banks seeking faster, scalable solutions.

Regulatory Progress With FDA 510(k) submission for MosaiQ AiPlex Vasculitis and ongoing global regulatory activity, there is a clear sales window for market access consultancy, regional distributors, and post-market services to support customers navigating approvals.

Distribution Partnerships Strategic distribution agreements, such as the MediServ partnership, indicate a channel-rich path to reach untapped regional markets; prioritize expanding partner network for lab networks, reference accounts, and localized support.

End-to-End Value The MosaiQ end-to-end automated platform combined with Alba reagents positions AliveDx as a one-stop solution for labs seeking streamlined workflows, reduced time-to-result, and integrated inventory, creating cross-sell opportunities across the portfolio.

Mid-Sized Focus With revenue in the 10–25M range and a mid-sized employee base, target mid-tier hospitals, blood banks, and regional diagnostic centers that require scalable, cost-efficient IVD solutions and robust service/support ecosystems.